Breast cancer is a major cause of death associated with cancer in women each year. Triple-negative breast cancer (TNBC) is considered as a subtype of breast cancer representing about 15% of breast cancer. It is not yet certain whether the poor prognosis of TNBC is due to the aggressive behavior or because of the lack of the targeted therapy. These malignant tumors pose a major health problem and targeting these tumors with traditional chemotherapy cannot be the only treatment as it has serious side effects. Accordingly, the present study aimed to evaluate the in vitro anticancer activity of organoselenium compounds against MDA-MB-231 and 4T1 TNBC cell lines. Compared with commercial anticancer drug cisplatin, 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-selenocyanatophenyl) urea showed anticancer action. Additionally, the inhibition activities were dose and time dependent as measured by MTT assay. These results suggest that the toxicity induced by 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-selenocyanatophenyl) urea might be efficient in the management of TNBC by utilizing several therapeutic approaches lowering the side effects related to existing TNBC treatments